CS263952B1 - Remedy with antiviral effect - Google Patents

Remedy with antiviral effect Download PDF

Info

Publication number
CS263952B1
CS263952B1 CS853018A CS301885A CS263952B1 CS 263952 B1 CS263952 B1 CS 263952B1 CS 853018 A CS853018 A CS 853018A CS 301885 A CS301885 A CS 301885A CS 263952 B1 CS263952 B1 CS 263952B1
Authority
CS
Czechoslovakia
Prior art keywords
formula
compounds
virus
cells
effect
Prior art date
Application number
CS853018A
Other languages
Czech (cs)
English (en)
Inventor
Antonin Rndr Drsc Holy
Ivan Ing Rosenberg
Original Assignee
Holy Antonin
Rosenberg Ivan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Holy Antonin, Rosenberg Ivan filed Critical Holy Antonin
Priority to CS853018A priority Critical patent/CS263952B1/cs
Priority to IL78553A priority patent/IL78553A/xx
Priority to US06/854,087 priority patent/US4724233A/en
Priority to AU56468/86A priority patent/AU586860B2/en
Priority to DK184186A priority patent/DK167342B1/da
Priority to CA000507510A priority patent/CA1272956A/en
Priority to PT82457A priority patent/PT82457B/pt
Priority to GR861089A priority patent/GR861089B/el
Priority to PH33699A priority patent/PH23112A/en
Priority to NZ215939A priority patent/NZ215939A/xx
Priority to EG241/86A priority patent/EG18436A/xx
Priority to AT86105776T priority patent/ATE73663T1/de
Priority to ZA863133A priority patent/ZA863133B/xx
Priority to DE8686105776T priority patent/DE3684363D1/de
Priority to EP86105776A priority patent/EP0205826B1/de
Priority to JP61097811A priority patent/JPH0692307B2/ja
Publication of CS263952B1 publication Critical patent/CS263952B1/cs
Priority to HK217296A priority patent/HK217296A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CS853018A 1985-04-25 1985-04-25 Remedy with antiviral effect CS263952B1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CS853018A CS263952B1 (en) 1985-04-25 1985-04-25 Remedy with antiviral effect
IL78553A IL78553A (en) 1985-04-25 1986-04-21 Therapeutic compositions of phosphonylmethoxyalkyl adenines
US06/854,087 US4724233A (en) 1985-04-25 1986-04-21 Therapeutical application of phosphonylmethoxyalkyl adenines
AU56468/86A AU586860B2 (en) 1985-04-25 1986-04-22 Therapeutical application of phosphonylmethoxyalkyl adenines
DK184186A DK167342B1 (da) 1985-04-25 1986-04-22 Terapeutisk praeparat til behandling af virussygdomme samt anvendelse af et 9-(fosfonylmetoxyalkyl)adeninderivat til fremstilling af praeparatet
GR861089A GR861089B (en) 1985-04-25 1986-04-24 Therapeutic application of phosponylmethoxy alkyl ademines
PT82457A PT82457B (pt) 1985-04-25 1986-04-24 Processo de preparacao de uma composicao farmaceutica com base em fosfonil-metoxi-alquil-adeninas com actividade antiviral
CA000507510A CA1272956A (en) 1985-04-25 1986-04-24 Therapeutical application of phosphonylmethoxy-alkyl adenines
PH33699A PH23112A (en) 1985-04-25 1986-04-24 Therapeutical application of phosphonylmethoxyalkyl adenines
NZ215939A NZ215939A (en) 1985-04-25 1986-04-24 Phosphonyl methoxyadenine antiviral compositions
EG241/86A EG18436A (en) 1985-04-25 1986-04-24 Therapeutical application of phosponylmethoxy-alkyl adenines
AT86105776T ATE73663T1 (de) 1985-04-25 1986-04-25 Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
ZA863133A ZA863133B (en) 1985-04-25 1986-04-25 Therapeutical application of phosphonylmethoxyalkyl adenines
DE8686105776T DE3684363D1 (de) 1985-04-25 1986-04-25 Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
EP86105776A EP0205826B1 (de) 1985-04-25 1986-04-25 Phosphonylmethoxyalkyl-Adeninen zur Behandlung von Viruskrankheiten
JP61097811A JPH0692307B2 (ja) 1985-04-25 1986-04-25 アデニン誘導体の治療的適用
HK217296A HK217296A (en) 1985-04-25 1996-12-19 Phosphonylmethoxyalkyl adenines for the treatment of virus diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CS853018A CS263952B1 (en) 1985-04-25 1985-04-25 Remedy with antiviral effect

Publications (1)

Publication Number Publication Date
CS263952B1 true CS263952B1 (en) 1989-05-12

Family

ID=5369042

Family Applications (1)

Application Number Title Priority Date Filing Date
CS853018A CS263952B1 (en) 1985-04-25 1985-04-25 Remedy with antiviral effect

Country Status (17)

Country Link
US (1) US4724233A (de)
EP (1) EP0205826B1 (de)
JP (1) JPH0692307B2 (de)
AT (1) ATE73663T1 (de)
AU (1) AU586860B2 (de)
CA (1) CA1272956A (de)
CS (1) CS263952B1 (de)
DE (1) DE3684363D1 (de)
DK (1) DK167342B1 (de)
EG (1) EG18436A (de)
GR (1) GR861089B (de)
HK (1) HK217296A (de)
IL (1) IL78553A (de)
NZ (1) NZ215939A (de)
PH (1) PH23112A (de)
PT (1) PT82457B (de)
ZA (1) ZA863133B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047533A (en) * 1983-05-24 1991-09-10 Sri International Acyclic purine phosphonate nucleotide analogs
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
IL84477A (en) * 1986-11-18 1995-12-08 Bristol Myers Squibb Co History of Phosphonomethoxyalkylene Purinopyrimidine and Pharmaceutical Preparations Containing Them
US5650510A (en) * 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
US5284837A (en) * 1988-05-06 1994-02-08 Medivir Ab Derivatives of purine, process for their preparation and a pharmaceutical preparation
EP0353955A3 (de) * 1988-08-02 1991-08-14 Beecham Group Plc Chemische Verbindungen
US5688778A (en) * 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
DK0481214T3 (da) * 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
EP0630381B1 (de) * 1991-10-11 1997-04-09 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antivirale acyclische phosphonomethoxyalkyl substituierte, alkenyl und alkynyl purin und pyrimidin-derivate
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5514798A (en) * 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
CA2171868A1 (en) * 1993-09-17 1995-03-23 Petr Alexander Method for dosing therapeutic compounds
EP0754046A1 (de) * 1994-04-04 1997-01-22 FREEMAN, William R. Verwendung der phosphonylmethoxyalkyl-nukleoside zur behandlung des erhöhten innenaugendrucks
US5468752A (en) * 1994-04-04 1995-11-21 Freeman; William R. Treatment of conditions of abnormally increased intraocular pressure by administration of HPMPC and related phosphonylmethoxyalkylcytosines
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
US6635278B1 (en) 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
HRP20030047B1 (hr) 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
BRPI0210746B8 (pt) 2001-06-29 2021-05-25 Inst Of Organic Chemistry And Biochemistry Ascr derivados de 6-'2-(fosfonometóxi)alcóxi-pirimidina e seu método de preparação
IL164809A0 (en) * 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues
AU2003235501A1 (en) * 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
RU2225223C1 (ru) * 2002-06-14 2004-03-10 Закрытое акционерное общество Фирма "ВИТАФАРМА" Лиофилизированная антигерпетическая вакцина
WO2004043972A1 (fr) * 2002-11-12 2004-05-27 Tianjin Kinsly Pharmaceutical Co., Ltd. Nouvelle forme cristalline d'adefovir dipivoxil et sa composition
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
NZ543864A (en) 2003-06-16 2009-10-30 Leuven K U Res & Dev Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
MXPA06014013A (es) * 2004-06-08 2007-03-15 Metabasis Therapeutics Inc Sintesis mediada por acidos de lewis de esteres ciclicos.
CN100338080C (zh) * 2004-06-16 2007-09-19 山东中科泰斗化学有限公司 9-[2-(膦羧基甲氧基)乙基]腺嘌呤双环醇酯及其制备方法
PT2258376T (pt) 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
US8101745B2 (en) * 2004-12-16 2012-01-24 The Regents Of The University Of California Lung-targeted drugs
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
FR2908133B1 (fr) * 2006-11-08 2012-12-14 Centre Nat Rech Scient Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux
PT2514750E (pt) 2007-06-18 2014-01-23 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
CN102365283B (zh) 2009-03-26 2014-04-09 株式会社大熊制药 阿德福韦酯的新晶型及其制备方法
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
WO2012079035A1 (en) 2010-12-10 2012-06-14 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
KR20150130355A (ko) 2013-03-15 2015-11-23 더 리전트 오브 더 유니버시티 오브 캘리포니아 비환식 뉴클레오사이드 포스포네이트 디에스테르
WO2015038421A1 (en) 2013-09-10 2015-03-19 Dow Corning Corporation Wear-resistant silicon eutectic alloy components and methods of making the same
EP3623364A1 (de) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Organische verbindungen und deren verwendungen
WO2015195538A1 (en) 2014-06-17 2015-12-23 Dow Corning Corporation Decorative shape-cast articles made from silicon eutectic alloys, and methods for producing the same
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
MX377983B (es) 2014-09-15 2025-03-04 Univ California Análogos de nucleótidos.
US20180263985A1 (en) 2015-09-15 2018-09-20 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
EP3875462A1 (de) 2015-09-15 2021-09-08 The Regents of The University of California Nukleotidanaloga
EP3372227A1 (de) 2017-03-06 2018-09-12 MH10 Spolka z ograniczona odpowiedzialnoscia Tablettenformulierung von adefovir dipivoxil
WO2019139919A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
JPS52105195A (en) * 1976-03-01 1977-09-03 Wellcome Found Substituted purine
US4230708A (en) * 1977-10-20 1980-10-28 Stichting Rega V.Z.W. Therapeutic application of (S) -or (RS)-9-(2, 3-dihydroxypropyl) adenine for use as antiviral agents
CS233665B1 (en) * 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
CS238038B1 (en) * 1983-10-07 1985-11-13 Antonin Holy Medical drug with antivirus effect

Also Published As

Publication number Publication date
ZA863133B (en) 1987-02-25
PH23112A (en) 1989-04-19
DK167342B1 (da) 1993-10-18
AU586860B2 (en) 1989-07-27
ATE73663T1 (de) 1992-04-15
EP0205826B1 (de) 1992-03-18
IL78553A (en) 1989-09-28
EP0205826A2 (de) 1986-12-30
EG18436A (en) 1993-02-28
HK217296A (en) 1996-12-27
DK184186A (da) 1986-10-26
CA1272956A (en) 1990-08-21
DE3684363D1 (de) 1992-04-23
NZ215939A (en) 1988-09-29
AU5646886A (en) 1986-10-30
PT82457B (pt) 1988-03-03
JPH0692307B2 (ja) 1994-11-16
IL78553A0 (en) 1986-08-31
JPS61275218A (ja) 1986-12-05
US4724233A (en) 1988-02-09
DK184186D0 (da) 1986-04-22
GR861089B (en) 1986-08-26
EP0205826A3 (en) 1989-05-10
PT82457A (en) 1986-05-01

Similar Documents

Publication Publication Date Title
US4724233A (en) Therapeutical application of phosphonylmethoxyalkyl adenines
De Clercq Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
De Clercq S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents
Clercq et al. A novel selective broad-spectrum anti-DNA virus agent
De Clercq et al. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds
Park et al. Acyclovir in oral and ganglionic herpes simplex virus infections
AU3334093A (en) Creatine analogs having antiviral activity
De Clercq et al. Selective in vitro and in vivo activities of 5-(2-haloalkyl) pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus
Soike et al. Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]-cytosine (S-HPMPC) on simian varicella infection in monkeys
De Clercq The antiviral spectrum of (E)-5-(2-bromovinyl)-2′-deoxyuridine
Zakirova et al. Phosphoramidate derivatives of acyclovir: Synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro
JP4545434B2 (ja) 抗ウイルス活性を有する6−‘2−(ホスホノメトキシ)アルコキシピリミジン誘導体
AU623341B2 (en) Antiviral therapy for hepatitis b
EP0294443B1 (de) Verwendung von nukleosiden zur herstellung eines medikamentes zur behandlung von krankheiten, die durch einen retrovirus oder den hepatitis-b-virus verursacht werden
JPH0618786B2 (ja) 医薬組成物
Machida et al. In vitro antiherpesviral activity of 5-alkyl derivatives of 1-β-d-arabinofuranosyluracil
JPS59186985A (ja) ジメチルアミノメチレン化された抗ヘルペス化合物
Wingard et al. Activity of trifluorothymidine against cytomegalovirus
De Clercq et al. Effects of E-5-(2-bromovinyl)-2'-deoxyuridine and other selective anti-herpes compounds on the induction of retrovirus particles in mouse BALB/3T3 cells
Krečmerová Nucleoside and nucleotide analogues for the treatment of herpesvirus infections: Current stage and new prospects in the field of acyclic nucleoside phosphonates
CS238038B1 (en) Medical drug with antivirus effect
Ayisi et al. Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses
Brandi et al. A new homodimer of aciclovir as a prodrug with increased solubility and antiviral activity
Park et al. Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the treatment of experimental herpes simplex virus encephalitis in mice
Barnard et al. Acyclic phosphonomethylether nucleoside inhibitors of respiratory viruses

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20000425